THE VALUE OF EMBEDDED INTERVIEWS- CASE STUDY OF QUALITATIVE AND QUANTITATIVE ASSESSMENT OF THE PATIENT EXPERIENCE OF MEPOLIZUMAB SELF-ADMINISTRATION
Author(s)
Evitt LA1, Follows R2, Bentley JH2, Williams W3, Shalhoub H4, Celone M4, von Maltzahn R2
1GSK, London, UK, 2GSK, Uxbridge, UK, 3GSK, Collegeville, PA, USA, 4Evidera, Waltham, MA, USA
OBJECTIVES To describe the value and operational learnings of embedded interviews using mepolizumab trials as a case study. Mepolizumab is licensed to treat severe eosinophilic asthma in the US. Development of a prefilled autoinjector (AI) and prefilled syringe (PFS) has been undertaken to allow self-administration, which may improve the patient treatment experience. METHODS Quantitative questionnaires [AI: n=153; PFS: n=56] and complementary qualitative exit interviews [AI: n=25; PFS: n=7] assessing the patient experience of self-injection were embedded in two real-world use studies of mepolizumab administered via an AI [N=159] and PFS [N=56]. RESULTS
- Capturing the patient experience through clinical endpoints alongside quantitative and qualitative patient reported outcomes provided a fuller picture of the value of the mepolizumab AI and PFS.
- Qualitative interviews allowed improved interpretation of quantitative results.
- > 99% of injections via both devices were successfully self-administered at week 8.
- Quantitative (satisfaction): >96% of respondents were “satisfied”/“very satisfied” with using the device (AI/PFS) at home.
- AI qualitative response example:
- Quantitative (convenience): >96% of respondents reported receiving mepolizumab using the device at home (AI/PFS) as “moderately”/”very”/”extremely” convenient.
- AI qualitative response example:
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PNS231
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Stated Preference & Patient Satisfaction
Disease
No Specific Disease